GORE® EXCLUDER® Conformable 腹主动脉瘤腔内覆膜支架系统在美国关键性试验中针对近端锚定区≥10 mm且近端瘤颈成角≤60度解剖的亚组研究的3年结局
该研究为美国31个中心的前瞻性多中心IDE临床试验,纳入80例近端锚定区≥10 mm且近端瘤颈成角≤60度的腹主动脉瘤患者,评估GORE® EXCLUDER® Conformable AAA Endoprosthesis系统的中期结局。36个月时无I型/III型内漏及动脉瘤相关死亡,免于二次干预率为91.9%(95%CI 0.83-0.96),无器械断裂、移位≥10 mm或动脉瘤破裂,结论认为该器械具有足够的安全性和有效性。
要点
- 36个月无I型/III型内漏及动脉瘤相关死亡,免于二次干预率91.9%(95%CI 0.83-0.96)。
- 36个月时13例(26.5%)存在II型内漏,32例(58.2%)瘤囊回缩,6例(10.9%)瘤囊增大。
- 36个月内7例(8.8%)接受再干预,无器械断裂、移位≥10 mm或动脉瘤破裂。
核心结论
- 3年结局持续显示EXCC器械具有足够的安全性和有效性,无动脉瘤相关死亡或I型/III型内漏,表明该EVAR器械在美国监管试验中具有耐久性。
研究设计与样本
- 前瞻性、多中心、研究性器械豁免临床试验,在美国31个中心开展,影像由核心实验室评估,安全性由独立裁定。
- 2017年12月至2019年2月纳入80例腹主动脉瘤患者,近端锚定区≥10 mm且近端瘤颈成角≤60度。
- 终点包括患者生存、免于二次干预及支架移植物相关结局。
主要发现
- 80例患者中男性占88.8%,平均年龄73.5±8.14岁,平均最大主动脉直径57.7±8.0 mm(范围42.5-82.7)。
- 36个月无I型/III型内漏及动脉瘤相关死亡的比率均为100%。
- 36个月免于二次干预率为91.9%(95%CI 0.83-0.96)。
- 36个月时13例(26.5%)存在II型内漏,32例(58.2%)瘤囊回缩,17例(30.9%)直径无变化,6例(10.9%)瘤囊增大。
- 36个月内7例(8.8%)接受再干预,无器械断裂、移位≥10 mm或动脉瘤破裂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the midterm clinical outcomes from the GORE® EXCLUDER® Conformable AAA Endoprosthesis system (EXCC) pivotal regulatory trial in the United States (U.S.). METHODS: This is a prospective, multicenter, investigational device exemption clinical trial at 31 U S. sites with Core Laboratory assessment of imaging and independent adjudication of safety. The study enrolled patients with abdominal aortic aneurysms (AAA) with a minimum proximal landing zone ≥10 mm and proximal neck angulation of ≤60 degrees between December 2017 and February 2019 as part of a larger study to gain indications of the EXCC device. Endpoints included patient survival, freedom from secondary interventions, and stent-graft related outcomes. RESULTS: There were 80 patients enrolled (88.8% male, mean 73.5 ± 8.14 years-old). Mean maximum aortic diameter was 57.7±8.0 mm (range, 42.5-82.7). There was 100% freedom from type I and III endoleak and aneurysm-related mortality at 36-months. Freedom from secondary intervention was 91.9 ± (0.83, 0.96, 95% C.I.) at 36-months. There were no device fractures, migrations (≥10 mm), or aneurysm ruptures. At 36 months, thirteen patients (26.5%) had type 2 endoleak, 32 patients (58.2%) had AAA sac regression, 17 (30.9%) had no change in diameter, and 6 (10.9%) had sac enlargement. Seven patients (8.8%) through 36 months underwent reintervention. CONCLUSIONS: The 3-year outcomes have continued to show an adequate safety and efficacy profile of the EXCC device with no aneurysm related mortality or Type I/III endoleak. These results demonstrate durability for an EVAR device in US regulatory trials.
引用
- Yamanouchi D, Oderich GS, Han S, et al. Three-year outcomes of a US pivotal trial substudy for conformable endoprosthesis in ≥10 mm nonangulated neck anatomy. J Vasc Surg. 2024. PMID: 39306018. doi:10.1016/j.jvs.2024.06.166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。